Cargando…

COVID-19 and liver disease: where are we now?

Patients with end-stage liver disease and COVID-19 are at a higher risk of hospitalization, ventilation and death than those without chronic liver disease. Whether the aetiology of liver disease also affects the natural history of COVID-19 in cirrhosis is debated. Effective and universal vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Francesco Paolo, Burra, Patrizia, Zanetto, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929467/ https://www.ncbi.nlm.nih.gov/pubmed/35301465 http://dx.doi.org/10.1038/s41575-022-00607-9

Ejemplares similares

Vitamin D for COVID-19: where are we now?
por: Martineau, Adrian R., et al.
Publicado: (2022)

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Sex bias in clinical trials in gastroenterology and hepatology
por: Burra, Patrizia, et al.
Publicado: (2022)

Genomic testing for rare disease diagnosis—where are we now, and where should we be heading? The reflections of a behavioural scientist
por: Lewis, Celine
Publicado: (2023)

The impact of ICCPR's Global Audit of Cardiac Rehabilitation: where are we now and where do we need to go?
por: Turk-Adawi, Karam, et al.
Publicado: (2023)

COVID-19 herd immunity: where are we?
por: Fontanet, Arnaud, et al.
Publicado: (2020)

ECMO for severe ARDS associated with COVID-19: now we know we can, but should we?
por: Shekar, Kiran, et al.
Publicado: (2020)

Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma
por: Burra, Patrizia, et al.
Publicado: (2018)

Living with the COVID-19 pandemic: act now with the tools we have
por: Bedford, Juliet, et al.
Publicado: (2020)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?
por: Khawaja, Fareed, et al.
Publicado: (2022)

Comment on Sah et al. Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence? Pathogens 2022, 11, 924
por: Vera, Milagros Nilda, et al.
Publicado: (2022)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Pim kinases in hematological malignancies: where are we now and where are we going?
por: Mondello, Patrizia, et al.
Publicado: (2014)

Where are we now?
Publicado: (1977)

The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation
por: Battistella, Sara, et al.
Publicado: (2023)

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
por: Battistella, Sara, et al.
Publicado: (2023)

New Indications for Liver Transplantation
por: Zanetto, Alberto, et al.
Publicado: (2021)

Post-COVID-19 Condition: Where Are We Now?
por: Boaventura, Paula, et al.
Publicado: (2022)

COVID-19 – Where should we go now?
por: Allen, Claire, et al.
Publicado: (2020)

Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?
por: Falchetti, A., et al.
Publicado: (2021)

Immunotherapy after liver transplantation: Where are we now?
por: Au, Kin Pan, et al.
Publicado: (2021)

The time to do serosurveys for COVID-19 is now
por: Peeling, Rosanna W, et al.
Publicado: (2020)

Drugs for improving esophageal mucosa defense: where are we now and where are we going?
por: Savarino, Edoardo, et al.
Publicado: (2017)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Tuberculosis elimination: where are we now?
por: Matteelli, Alberto, et al.
Publicado: (2018)

The influenza imperative: we must prepare now for seasonal and pandemic influenza
por: Dzau, Victor, et al.
Publicado: (2023)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
por: Russo, Roberto, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2018)

Child malnutrition and COVID-19: the time to act is now
por: Fore, Henrietta H, et al.
Publicado: (2020)

Two years of COVID-19 pandemic: where are we now?
por: Myoung, Jinjong
Publicado: (2022)

The COVID-19 Vaccine in Clinical Trials: Where Are We Now?
por: Jiang, Hu-Dachuan, et al.
Publicado: (2021)

Lung cancer and Covid-19: lessons learnt from the pandemic and where do we go from here?
por: Maxwell, Susanne Sarah, et al.
Publicado: (2022)

Elective orthopaedic cancellations due to the COVID-19 pandemic: where are we now, and where are we heading?
por: Oussedik, Sam, et al.
Publicado: (2021)

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma
por: Zanetto, Alberto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t39vr872ikhriu9f6v15pkh8qi